Key facts

Innovation is the best medicine

Built on a foundation of deep research, RTW invests with innovative companies looking to bring important new products to patients

42

Core portfolio companies

76

Team members

10

Therapeutic areas addressed by core portfolio

15

MDs and PhDs

$5.9B

in assets under management

44/55

Portfolio companies’ pipeline products are in clinical stage programs

Active investors and company builders in the US, UK, Europe and Asia
Offices located in the New York, London, and Shanghai
~80% of portfolio is invested in the US but assets often originate in labs ex US
Incubating a new company in Shanghai
UK listed Venture fund in London

Long term investing to maximize value capture
Identifying high probability genetic targets to clinical stage therapies and bringing them to patients
Capabilities necessary to invest across the entire private to public lifecycle
World class expertise in rigorous scientific and commercial analysis

Deep scientific expertise and analysis
Evaluate opportunities through one of three lenses: disease area, modality, genetics
Preserve integrity of science
Collaboration is rewarded

Research team is complemented by asset development, corporate finance, business, and operations teams
Seeking win-win solutions for portfolio advancement and value creation
Creating companies around the best science and building them for the long term